Key facts
- It has raised $500K; the latest was Seed Round in Nov 2025.
- Notable investors include Y Combinator, Pioneer Fund.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Exonic
- ·The full record, as it builds
Funding rounds
No funding rounds for Exonic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Exonic
Developer of an open, artificial intelligence-powered drug discovery platform intended to democratize and accelerate the development of new therapeutics. The company's platform offers to transform drug discovery into a global, meritocratic tournament, share state-of-the-art biological AI models without coding, with real-world laboratory validation, enabling scientists and innovators to combine, prompt, and thereby turn the internet into a collaborative drug discovery powerhouse.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 3
- Website
- exonic.ai/
- Ownership
- Privately Held (backing)
Exonic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Exonic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Exonic in its N-PORT filings yet. We sweep new filings monthly.